Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib-an Analysis of the Randomized CML …
B Hanfstein, M Lauseker, R Hehlmann, S Saussele… - 2014 - ashpublications.org
Introduction: Early prediction of outcome using response-related predictive landmarks has
become a major paradigm in the clinical management of chronic myeloid leukemia (CML) …
become a major paradigm in the clinical management of chronic myeloid leukemia (CML) …
[HTML][HTML] Molecular response after 3 months of 1st line imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic …
B Hanfstein, MC Müller, P Erben, S Schnittger… - Blood, 2010 - Elsevier
Abstract Abstract 360 Introduction: The lack of a sufficient response to first line imatinib
treatment has been observed in a substantial proportion of CML patients and has been …
treatment has been observed in a substantial proportion of CML patients and has been …
The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid …
R Hehlmann, B Hanfstein, MC Müller, P Erben… - 2012 - ascopubs.org
6510 Background: In the face of competing first line treatment options for CML early
prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise …
prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise …
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B Hanfstein, MC Müller, R Hehlmann, P Erben… - Leukemia, 2012 - nature.com
In the face of competing first-line treatment options for CML, early prediction of prognosis on
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …
[HTML][HTML] The BCR-ABL transcript levels at 3 and 6 months predict the long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib mesylate: a …
F Castagnetti, G Gugliotta, M Breccia, G Specchia… - Blood, 2012 - Elsevier
Abstract Abstract 1678 Background. Imatinib mesylate (IM) is the therapeutic standard for
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
[HTML][HTML] Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia–an …
MC Müller, B Hanfstein, P Erben, S Schnittger… - Blood, 2008 - Elsevier
The introduction of imatinib has significantly changed prognosis of CML patients. Despite
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …
[HTML][HTML] Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
J Zhang, Y Wang, J Wang, J Hu, S Chen, J Jin… - Blood Cancer …, 2018 - nature.com
An early molecular response is spectacularly predictive of outcome in chronic myeloid
leukemia (CML) and early response landmarks may identify the high-risk patients likely to be …
leukemia (CML) and early response landmarks may identify the high-risk patients likely to be …
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?
R Latagliata, M Breccia, I Carmosino… - European Journal of …, 2018 - Wiley Online Library
Objectives To evaluate differences in clinical results according to age among patients with
chronic myeloid leukemia (CML). Methods 207 consecutive CML patients treated with …
chronic myeloid leukemia (CML). Methods 207 consecutive CML patients treated with …
[HTML][HTML] Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML …
R Hehlmann, M Lauseker, S Saußele, M Pfirrmann… - Leukemia, 2017 - nature.com
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with
imatinib (IM) at 400 mg/day (n= 400) could be optimized by doubling the dose (n= 420) …
imatinib (IM) at 400 mg/day (n= 400) could be optimized by doubling the dose (n= 420) …
[HTML][HTML] Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic …
B Hanfstein, MC Müller, P Erben, M Lauseker… - Blood, 2011 - Elsevier
Abstract Abstract 783 FN2 Introduction: The advent of second generation tyrosine kinase
inhibitors (TKI) in the front line treatment setting of chronic myeloid leukemia (CML) has …
inhibitors (TKI) in the front line treatment setting of chronic myeloid leukemia (CML) has …